The nucleic acid based gene therapy market size has grown rapidly in recent years. It will grow from $0.88 billion in 2025 to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in molecular biology research, increased understanding of genetic disease mechanisms, expansion of clinical trials for gene therapies, rising investment in biotechnology research, early regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of crispr-based treatments, rising demand for rare disease therapies, expansion of gene therapy manufacturing facilities, growing focus on personalized oncology treatments, increasing public and private funding for genetic medicine. Major trends in the forecast period include increasing adoption of rna-based therapeutics, rising use of viral and non-viral gene delivery systems, growing focus on targeted gene editing technologies, expansion of personalized genetic therapies, enhanced emphasis on precision medicine applications.
The increasing financial support from governments and companies is anticipated to drive the growth of the nucleic acid-based gene therapy market in the coming years. Financial support includes investments, grants, and subsidies provided by public or private organizations to promote the research, development, and commercialization of therapies. The growth in financial support is attributed to the rising global focus on addressing rare and genetic diseases that currently have limited or no effective treatments. Government funding for nucleic acid-based gene therapy accelerates advancement by providing critical resources for research, clinical trials, and infrastructure, which directly foster innovation and the translation of therapies into clinical applications. For example, in July 2023, according to the U.S. National Institutes of Health, a U.S.-based federal health research agency, more than $140 million was allocated to accelerate genome-editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, representing a notable increase from the $92 million awarded in 2022. Therefore, the rising financial support from governments and companies is contributing to the expansion of the nucleic acid-based gene therapy market.
Major companies operating in the nucleic acid-based gene therapy market are prioritizing personalized, autologous stem cell therapies, such as genetically modified hematopoietic stem cell infusions, to address rare inherited disorders. Autologous therapies involve treatments in which a patient’s own stem cells are harvested, genetically corrected, and then reintroduced to restore the missing biochemical function. For example, in March 2024, Orchard Therapeutics, a US-based pharmaceutical company, announced that Lenmeldy (atidarsagene autotemcel) received approval from the U.S. Food and Drug Administration for the treatment of children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient’s own hematopoietic stem cells that are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration within the nervous system. This regulatory milestone highlights how companies are able to commercialize complex autologous gene therapies despite high manufacturing costs.
In March 2023, Moderna, Inc., a US-based biotechnology company, announced a partnership with Generation Bio. This collaboration aims to develop innovative nucleic acid therapeutics, including therapies designed to target immune cells, to advance both companies' pipelines of non-viral genetic medicines. Under the agreement, Moderna will fund all research and development activities related to this partnership, including a pre-payment to support research efforts. Generation Bio, also a US-based biotechnology company, specializes in nucleic acid-based gene therapies.
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucleic acid based gene therapy market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are impacting the nucleic acid based gene therapy market by increasing costs of imported laboratory reagents, delivery vectors, bioprocessing equipment, nucleic acid synthesis tools, and advanced analytical instruments. Research institutes and biotech manufacturers in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented biopharmaceutical production. These tariffs are increasing development costs and lengthening commercialization timelines. However, they are also driving domestic manufacturing of reagents, local bioprocess innovation, and regional capacity building in gene therapy production infrastructure.
The nucleic acid based gene therapy market research report is one of a series of new reports that provides nucleic acid based gene therapy market statistics, including nucleic acid based gene therapy industry global market size, regional shares, competitors with a nucleic acid based gene therapy market share, detailed nucleic acid based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid based gene therapy industry. This nucleic acid based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gene therapy aims to correct faulty genes responsible for disease development, while nucleic acid-based therapeutics are employed to address genetic disorders and conditions without a definitive cure, such as anemia, sickle cell disease, cystic fibrosis, and thalassemia.
The key technologies include anti-sense and anti-gene strategies, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and other innovative approaches. Nucleoside analogues, a significant class of antiviral agents, are commonly utilized to combat conditions like human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV) infections. These therapeutic approaches find applications in various medical fields, including oncology, the management of conditions like muscular dystrophy and muscular disorders, and the treatment of rare diseases. They are implemented by end-users, including hospitals, clinics, academic institutions, and research centers, where cutting-edge research and development efforts are often carried out.
The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The nucleic acid based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of crispr-based treatments, rising demand for rare disease therapies, expansion of gene therapy manufacturing facilities, growing focus on personalized oncology treatments, increasing public and private funding for genetic medicine. Major trends in the forecast period include increasing adoption of rna-based therapeutics, rising use of viral and non-viral gene delivery systems, growing focus on targeted gene editing technologies, expansion of personalized genetic therapies, enhanced emphasis on precision medicine applications.
The increasing financial support from governments and companies is anticipated to drive the growth of the nucleic acid-based gene therapy market in the coming years. Financial support includes investments, grants, and subsidies provided by public or private organizations to promote the research, development, and commercialization of therapies. The growth in financial support is attributed to the rising global focus on addressing rare and genetic diseases that currently have limited or no effective treatments. Government funding for nucleic acid-based gene therapy accelerates advancement by providing critical resources for research, clinical trials, and infrastructure, which directly foster innovation and the translation of therapies into clinical applications. For example, in July 2023, according to the U.S. National Institutes of Health, a U.S.-based federal health research agency, more than $140 million was allocated to accelerate genome-editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, representing a notable increase from the $92 million awarded in 2022. Therefore, the rising financial support from governments and companies is contributing to the expansion of the nucleic acid-based gene therapy market.
Major companies operating in the nucleic acid-based gene therapy market are prioritizing personalized, autologous stem cell therapies, such as genetically modified hematopoietic stem cell infusions, to address rare inherited disorders. Autologous therapies involve treatments in which a patient’s own stem cells are harvested, genetically corrected, and then reintroduced to restore the missing biochemical function. For example, in March 2024, Orchard Therapeutics, a US-based pharmaceutical company, announced that Lenmeldy (atidarsagene autotemcel) received approval from the U.S. Food and Drug Administration for the treatment of children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient’s own hematopoietic stem cells that are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration within the nervous system. This regulatory milestone highlights how companies are able to commercialize complex autologous gene therapies despite high manufacturing costs.
In March 2023, Moderna, Inc., a US-based biotechnology company, announced a partnership with Generation Bio. This collaboration aims to develop innovative nucleic acid therapeutics, including therapies designed to target immune cells, to advance both companies' pipelines of non-viral genetic medicines. Under the agreement, Moderna will fund all research and development activities related to this partnership, including a pre-payment to support research efforts. Generation Bio, also a US-based biotechnology company, specializes in nucleic acid-based gene therapies.
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucleic acid based gene therapy market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are impacting the nucleic acid based gene therapy market by increasing costs of imported laboratory reagents, delivery vectors, bioprocessing equipment, nucleic acid synthesis tools, and advanced analytical instruments. Research institutes and biotech manufacturers in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented biopharmaceutical production. These tariffs are increasing development costs and lengthening commercialization timelines. However, they are also driving domestic manufacturing of reagents, local bioprocess innovation, and regional capacity building in gene therapy production infrastructure.
The nucleic acid based gene therapy market research report is one of a series of new reports that provides nucleic acid based gene therapy market statistics, including nucleic acid based gene therapy industry global market size, regional shares, competitors with a nucleic acid based gene therapy market share, detailed nucleic acid based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid based gene therapy industry. This nucleic acid based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gene therapy aims to correct faulty genes responsible for disease development, while nucleic acid-based therapeutics are employed to address genetic disorders and conditions without a definitive cure, such as anemia, sickle cell disease, cystic fibrosis, and thalassemia.
The key technologies include anti-sense and anti-gene strategies, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and other innovative approaches. Nucleoside analogues, a significant class of antiviral agents, are commonly utilized to combat conditions like human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV) infections. These therapeutic approaches find applications in various medical fields, including oncology, the management of conditions like muscular dystrophy and muscular disorders, and the treatment of rare diseases. They are implemented by end-users, including hospitals, clinics, academic institutions, and research centers, where cutting-edge research and development efforts are often carried out.
The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Nucleic Acid Based Gene Therapy Market Characteristics
3. Nucleic Acid Based Gene Therapy Market Supply Chain Analysis
4. Global Nucleic Acid Based Gene Therapy Market Trends and Strategies
5. Nucleic Acid Based Gene Therapy Market Analysis of End Use Industries
7. Global Nucleic Acid Based Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Nucleic Acid Based Gene Therapy Total Addressable Market (TAM) Analysis for the Market
9. Nucleic Acid Based Gene Therapy Market Segmentation
10. Nucleic Acid Based Gene Therapy Market Regional and Country Analysis
11. Asia-Pacific Nucleic Acid Based Gene Therapy Market
12. China Nucleic Acid Based Gene Therapy Market
13. India Nucleic Acid Based Gene Therapy Market
14. Japan Nucleic Acid Based Gene Therapy Market
15. Australia Nucleic Acid Based Gene Therapy Market
16. Indonesia Nucleic Acid Based Gene Therapy Market
17. South Korea Nucleic Acid Based Gene Therapy Market
18. Bangladesh Nucleic Acid Based Gene Therapy Market
19. Thailand Nucleic Acid Based Gene Therapy Market
20. Vietnam Nucleic Acid Based Gene Therapy Market
21. Malaysia Nucleic Acid Based Gene Therapy Market
22. Singapore Nucleic Acid Based Gene Therapy Market
23. Philippines Nucleic Acid Based Gene Therapy Market
24. Hong Kong Nucleic Acid Based Gene Therapy Market
25. New Zealand Nucleic Acid Based Gene Therapy Market
26. Taiwan Nucleic Acid Based Gene Therapy Market
27. South East Asia Nucleic Acid Based Gene Therapy Market
28. Western Europe Nucleic Acid Based Gene Therapy Market
29. UK Nucleic Acid Based Gene Therapy Market
30. Germany Nucleic Acid Based Gene Therapy Market
31. France Nucleic Acid Based Gene Therapy Market
32. Italy Nucleic Acid Based Gene Therapy Market
33. Spain Nucleic Acid Based Gene Therapy Market
34. Austria Nucleic Acid Based Gene Therapy Market
35. Belgium Nucleic Acid Based Gene Therapy Market
36. Denmark Nucleic Acid Based Gene Therapy Market
37. Finland Nucleic Acid Based Gene Therapy Market
38. Ireland Nucleic Acid Based Gene Therapy Market
39. Netherlands Nucleic Acid Based Gene Therapy Market
40. Norway Nucleic Acid Based Gene Therapy Market
41. Portugal Nucleic Acid Based Gene Therapy Market
42. Sweden Nucleic Acid Based Gene Therapy Market
42. Switzerland Nucleic Acid Based Gene Therapy Market
43. Eastern Europe Nucleic Acid Based Gene Therapy Market
44. Russia Nucleic Acid Based Gene Therapy Market
45. Czech Republic Nucleic Acid Based Gene Therapy Market
46. Poland Nucleic Acid Based Gene Therapy Market
47. Romania Nucleic Acid Based Gene Therapy Market
48. Ukraine Nucleic Acid Based Gene Therapy Market
49. North America Nucleic Acid Based Gene Therapy Market
50. USA Nucleic Acid Based Gene Therapy Market
51. Canada Nucleic Acid Based Gene Therapy Market
52. Mexico Nucleic Acid Based Gene Therapy Market
53. South America Nucleic Acid Based Gene Therapy Market
54. Brazil Nucleic Acid Based Gene Therapy Market
55. Chile Nucleic Acid Based Gene Therapy Market
56. Argentina Nucleic Acid Based Gene Therapy Market
57. Colombia Nucleic Acid Based Gene Therapy Market
58. Peru Nucleic Acid Based Gene Therapy Market
59. Middle East Nucleic Acid Based Gene Therapy Market
60. Saudi Arabia Nucleic Acid Based Gene Therapy Market
61. Israel Nucleic Acid Based Gene Therapy Market
62. Iran Nucleic Acid Based Gene Therapy Market
63. Turkey Nucleic Acid Based Gene Therapy Market
64. United Arab Emirates Nucleic Acid Based Gene Therapy Market
65. Africa Nucleic Acid Based Gene Therapy Market
66. Egypt Nucleic Acid Based Gene Therapy Market
67. Nigeria Nucleic Acid Based Gene Therapy Market
68. South Africa Nucleic Acid Based Gene Therapy Market
70. Nucleic Acid Based Gene Therapy Market Competitive Landscape and Company Profiles
71. Nucleic Acid Based Gene Therapy Market Other Major and Innovative Companies
74. Nucleic Acid Based Gene Therapy Market High Potential Countries, Segments and Strategies
75. Appendix
List of Tables
Executive Summary
Nucleic Acid Based Gene Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses nucleic acid based gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nucleic acid based gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid based gene therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Anti-Sence and Anti-Gene; Short Inhibitory Sequences; Gene Transfer Therapy; Nucleoside Analogs; Ribozymes; Aptamers; Other Technologies2) By Application: Oncology; Muscular Dystrophy/ Muscular Disorders; Rare Diseases
3) By End User: Hospitals And Clinics; Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics; Peptide Nucleic Acids (PNA); Morpholino Oligomers (MO)2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA; Encapsulation/Delivery Systems for siRNA; Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV); Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs; Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes; Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers; DNA Aptamers; Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing; Zinc Finger Nucleases (ZFN); Transcription Activator-Like Effector Nucleases (TALENs)
Companies Mentioned: Celsion Corporation; Wave Life Sciences; Imugene Ltd.; Caperna LLC; Phylogica Limited; Protagonist Therapeutics Inc.; Benitec Biopharma Ltd.; EGEN; BioMedica; Transgene SA; Copernicus Therapeutics Inc.; 4D Molecular Therapeutics Inc.; Abeona Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Amgen Inc.; Beam Therapeutics Inc.; BioNTech SE; Bluebird Bio Inc.; CRISPR Therapeutics AG; Editas Medicine Inc.; Genevant Sciences Inc.; Homology Medicines Inc.; Intellia Therapeutics Inc.; Ionis Pharmaceuticals Inc.; MaxCyte Inc.; Moderna Inc.; Novartis International AG; Orchard Therapeutics plc; Precision BioSciences Inc.; REGENXBIO Inc.
Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Nucleic Acid Based Gene Therapy market report include:- Celsion Corporation
- Wave Life Sciences
- Imugene Ltd.
- Caperna LLC
- Phylogica Limited
- Protagonist Therapeutics Inc.
- Benitec Biopharma Ltd.
- EGEN
- BioMedica
- Transgene SA
- Copernicus Therapeutics Inc.
- 4D Molecular Therapeutics Inc.
- Abeona Therapeutics Inc.
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Beam Therapeutics Inc.
- BioNTech SE
- Bluebird Bio Inc.
- CRISPR Therapeutics AG
- Editas Medicine Inc.
- Genevant Sciences Inc.
- Homology Medicines Inc.
- Intellia Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- MaxCyte Inc.
- Moderna Inc.
- Novartis International AG
- Orchard Therapeutics plc
- Precision BioSciences Inc.
- REGENXBIO Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.97 Billion |
| Forecasted Market Value ( USD | $ 1.44 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
